Dark
Light
Today: November 9, 2024
February 15, 2024
1 min read

Igniting Potential: $94M Funds Firefly Bio’s Protein Breakthrough with ADC Dream Team

TLDR: Firefly Bio has emerged from stealth mode with $94 million in funding co-led by Versant Ventures and MPM BioImpact. The company has assembled an “ADC dream team” to work on developing degrader-antibody conjugates (DACs), a new class of therapies to fight cancer. The team, led by CEO Scott Hirsch, includes scientists with backgrounds at Genentech, Merck & Co., and AbbVie, as well as Nobel laureate Carolyn Bertozzi. Firefly’s platform focuses on protein degraders, which use the cell’s natural degradation machinery to eliminate disease-causing proteins. The company aims to deliver a more selective payload that can improve the therapeutic index and clinical outcomes for patients.

Previous Story

Evergrowth secures $22M seed investment, propelling exponential growth

Next Story

Revolutionary Kubernetes Security: KTrust raises $53m in seed funding

Latest from Blog

Go toTop